Malcolm T. Brown is a partner at Wolf Haldenstein. He graduated from University of Pennsylvania (B.A.1988) and Rutgers University School of Law (J.D. 1994). His practice areas include: Foreign Securities Litigation, U.S. Securities Litigation, Derivative Litigation, Corporate Takeover Litigation, Unfair & Deceptive Practices, Defective Products, and Civil Rights. His bar admissions are : State of New York, State of New Jersey, Commonwealth of Pennsylvania, U. S. District Courts for the Southern, Eastern and Northern Districts of New York,, District of New Jersey, Eastern District of Pennsylvania, and U.S. Court of Appeals for the Second Circuit.
Subject: Sherrod Brown (D-OH)
Subject of Interest
U. S. Senator Sherrod Brown (D-OH) is a minority member of the US Senate Committee on Banking. He was elected to the Senate in 2007. Prior to serving in the United States Senate, Brown served as a United States Representative for the 13th District, Ohio’s Secretary of State, a member of the Ohio General Assembly, and has taught in Ohio’s public schools and at The Ohio State University. He also serves on the Senate Committee on Finance and has served on the Senate Agriculture, Nutrition, and Forestry Committee, and he served Chairman of the Subcommittee on Jobs, Rural Economic Growth and Energy Innovation.
Article: H.C. Wainwright Sticks to Their Buy Rating for Pluristem (PSTI)
Article - MediaH.C. Wainwright Sticks to Their Buy Rating for Pluristem (PSTI)
Christine Brown
SmarterAnalyst, 1 May 2020
In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Pluristem (PSTI), with a price target of $15.50. The company’s shares closed last Thursday at $9.17.
According to TipRanks.com, Ramakanth is a 1-star analyst with an average return of -0.7% and a 36.0% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, IntelGenx Technologies, and Corvus Pharmaceuticals.
Comment: This company is at risk of collusion between a placement agent and naked short sellers.
Article: H.C. Wainwright Keeps a Buy Rating on CareDx (CDNA)
Article - MediaH.C. Wainwright Keeps a Buy Rating on CareDx (CDNA)
Christine Brown
SmarterAnalyst, 1 May 2020
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on CareDx (CDNA), with a price target of $40.00. The company’s shares closed last Thursday at $25.38.
According to TipRanks.com, Chen is a 5-star analyst with an average return of 14.1% and a 43.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, HTG Molecular Diagnostics, and EyePoint Pharmaceuticals.
Comment: This company is at risk of collusion between a placement agent and naked short sellers.
Article: H.C. Wainwright Maintains a Buy Rating on BerGenBio AS (BRRGF)
Article - MediaH.C. Wainwright Maintains a Buy Rating on BerGenBio AS (BRRGF)
Christine Brown
SmarterAnalyst, 29 April 2020
H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on BerGenBio AS (BRRGF) today and set a price target of NOK66.00. The company’s shares closed last Monday at $1.23.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 8.2% and a 41.6% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Iovance Biotherapeutics.
Comment: This company is at risk of collusion between a placement agent and naked short sellers.
RELATED:
Article: Bank of America Eroded U.S. Spoof Case, Laying Path for JPMorgan
Article - MediaBank of America Eroded U.S. Spoof Case, Laying Path for JPMorgan
Tom Schoenberg
Bloomberg, 20 February 2020
Bank of America Corp.’s lawyers came through big for their client last year when they whittled down a U.S. case over precious metals spoofing.
Justice Department prosecutors wanted to bring criminal charges, but bank lawyers asked for none and prevailed. Prosecutors named Bank of America throughout the draft settlement document but not in the final version.
Article: Secrets and Lies of the Bailout
Article - MediaSecrets and Lies of the Bailout
Matt Taibbi
Rolling Stone, 4 January 2013
It has been four long winters since the federal government, in the hulking, shaven-skulled, Alien Nation-esque form of then-Treasury Secretary Hank Paulson, committed $700 billion in taxpayer money to rescue Wall Street from its own chicanery and greed. To listen to the bankers and their allies in Washington tell it, you’d think the bailout was the best thing to hit the American economy since the invention of the assembly line. Not only did it prevent another Great Depression, we’ve been told, but the money has all been paid back, and the government even made a profit. No harm, no foul – right?
Article: The Secret Bailout of J. P. Morgan: How Insider Trading Looted Bear Stearns and the American Taxpayer
Article - MediaEllen Brown
Global Research, 14 May 2008
The mother of all insider trades was pulled off in 1815, when London financier Nathan Rothschild led British investors to believe that the Duke of Wellington had lost to Napoleon at the Battle of Waterloo. In a matter of hours, British government bond prices plummeted. Rothschild, who had advance information, then swiftly bought up the entire market in government bonds, acquiring a dominant holding in England’s debt for pennies on the pound. Over the course of the nineteenth century, N. M. Rothschild would become the biggest bank in the world, and the five brothers would come to control most of the foreign-loan business of Europe. “Let me issue and control a nation’s money,” Rothschild boasted in 1838, “and I care not who writes its laws.”
Article: Overstock.com dukes it out with short sellers
Article - Media, PublicationsOverstock.com dukes it out with short sellers
The Associated Press, 12 June 2006
Most people buy stock hoping the price goes up, but hedge fund manager David Rocker was “shorting” shares of Utah-based Internet retailer Overstock.com Inc., betting the share price would decline.
Rocker’s fund was making a legal bet that Overstock shares in 2004 were overvalued and due for a correction. Overstock.com CEO Patrick Byrne, however, sued, accusing New York-based Rocker Partners of collaborating on disparaging reports with the stock-research firm Gradient Analytics of Scottsdale, Ariz., while Rocker was shorting the shares. Continue reading “Article: Overstock.com dukes it out with short sellers”
